BioAdvance News

Treventis Awarded $2.97M Grant from the U.S. Department of Defense

By WebmasterOctober 18, 2022November 1st, 2024No Comments

Treventis Awarded $2.97M Grant from the U.S. Department of Defense

Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases

Previous PostVenatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Next PostWellsheet Introduces EHR Workflow Relief to Increase Efficiency During Critical Nursing Shortage